The haunting of medical journals: How ghostwriting sold "HRT"

PLoS Medicine

Volumn 7, Issue 9, 2010, Pages

  Fugh Berman, Adriane J ^a  

^a GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONJUGATED ESTROGEN; CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; GESTAGEN; MEDROXYPROGESTERONE ACETATE; RALOXIFENE; TAMOXIFEN; TRIMEGESTONE;

ALZHEIMER DISEASE; ARTICLE; BREAST CANCER; CANCER RISK; DEMENTIA; DRUG APPROVAL; DRUG EFFICACY; DRUG MARKETING; DRUG RESEARCH; DRUG SAFETY; HEALTH CARE COST; HEART PROTECTION; HORMONAL THERAPY; HORMONE RESPONSE; HORMONE SUBSTITUTION; HOT FLUSH; HUMAN; INCONTINENCE; LOW DRUG DOSE; MEDICAL HISTORY; MEDICAL LITERATURE; MENOPAUSE; OFF LABEL DRUG USE; OSTEOPOROSIS; PARKINSON DISEASE; PUBLICATION; QUALITY OF LIFE; RETINA MACULA AGE RELATED DEGENERATION; RISK FACTOR; SELF ESTEEM; UTERUS CANCER; DRUG INDUSTRY; ETHICS; LEGAL ASPECT; PUBLISHING; SCIENTIFIC MISCONDUCT; STANDARD;

DRUG INDUSTRY; EDITORIAL POLICIES; HORMONE REPLACEMENT THERAPY; HUMANS; JOURNALISM, MEDICAL; PERIODICALS AS TOPIC; SCIENTIFIC MISCONDUCT;

EID: 77957898639     PISSN: 15491277     EISSN: 15491676     Source Type: Journal    
DOI: 10.1371/journal.pmed.1000335     Document Type: Article

References (109)

1. Fugh-Berman A, Scialli AR (2006) Gynecologists and estrogen: an affair of the heart. Perspect Biol Med 49: 115-130.
2. Hulley S, Grady D, Bush T, Furberg C, Herrington D, et al. (1998) Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 280: 605-613.
3. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, et al. (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 288: 321-333.
4. The Women's Health Initiative Steering Committee (2004) Effects of Conjugated Equine Estrogen in Postmenopausal Women With Hysterectomy: The Women's Health Initiative Randomized Controlled Trial. JAMA 291: 1701-1712.
5. Shumaker SA, Legault C, Kuller L, Rapp SR, Thal L, et al. (2004) Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study. JAMA 291: 2947-2958.
6. Hendrix SL, Cochrane BB, Nygaard IE, Handa VL, Barnabei VM, et al. (2005) Effects of estrogen with and without progestin on urinary incontinence. JAMA 293: 935-948.
7. Power ML, Anderson BL, Schulkin J (2009) Attitudes of obstetrician-gynecologists toward the evidence from the Women's Health Initiative hormone therapy trials remain generally skeptical. Menopause 16: 500-508.
8. Power ML, Baron J, Schulkin J (2008) Factors associated with obstetrician-gynecologists' response to the Women's Health Initiative trial of combined hormone therapy. Med Decis Making 28: 411-418.
9. Fugh-Berman A, Dodgson S (2008) The ethics of publication planning in the pharmaceutical industry. Open Medicine 2(4): e33-6.
10. Matheson Alastair (2008) Corporate Science and the Husbandry of Scientific and Medical Knowledge by the Pharmaceutical Industry. Biosocieties 3: 355-82.
11. Fugh-Berman A (2005) The corporate coauthor. J Gen Intern Med 20: 546-548.
12. Sismondo S (2007) Ghost management: how much of the medical literature is shaped behind the scenes by the pharmaceutical industry? PLoS Med 4: e286.
13. LAWT203-0000254-0000266 at LAWT203- 0000255 (DesignWrite Powerpoint. Expanding Choices. 2003 Strategic Publications Plan for Women's Health Care. November 22, 2002). Available: http://dida.library.ucsf.edu/tid/ssb37b10. Accessed 21 Aug 2009.
14. DesignWrite [Internet]. Princeton, NJ: Jobson Healthcare Information LLC, c1997- 2009. Available: http://www.jmihealth.com/marketingcommunication/communication/designwrit e. php. Accessed 15 Aug 2009.
15. DWRITE065923 (The 1997 Premarin Publication Program) [Internet]. San Francisco: Drug Industry Document Archive. Available: http://dida.library.ucsf.edu/tid/juc37b10. Accessed 21 Aug 2009.
16. Mittleman5022006 at 188:8-188:10, 190-91; 214; 221; 222; 223-4. May 2, 2006 [Internet]. San Francisco: Drug Industry Document Archive. Available: http://dida.library.ucsf.edu/tid/zkb37b10. Accessed 21 Aug 2009.
17. DWRITE019241 at DWRITE019242 (Continuing Medical Education in Women's Health Care Proposal for 2004 satellite symposia) [Internet]. San Francisco: Drug Industry Document Archive. Available: http://dida.library. ucsf.edu/tid/iwb37b10. Accessed 21 Aug 2009.
18. STRIS014-000675 (HOPE Trial Publication Plan Proposal Year 1 Data) [Internet]. San Francisco: Drug Industry Document Archive. 2000. Available: http://dida.library.ucsf.edu/tid/wqc37b10. Also DWRITE066150 at DWRITE066150 and DWRITE066152 (2003 Publication Plan). Available: http://dida.library. ucsf.edu/tid/kic37b10. Other supporting documentation: DWRITE066162 Available: http://dida.library.ucsf.edu/tid/kjb37b10. Accessed 15 Feb 2010.
19. DELCA031-019050 and DELCA031-019052- 019068 (Endometrial Effects of Lower Doses of Conjugated Estrogens and Medroxyprogester- one Acetate); DELCA004-001404 and DELCA004-001405-001432 (Effects of Lower Doses of Conjugated Estrogens and Medroxyprogesterone Acetate on Vasomotor Symptoms and Vaginal Atrophy); DELCA032-028548 and DELCA032-028549-028569 (Effects of Lower Doses of Conjugated Estrogens and Medroxyprogesterone Acetate on Plasma Lipids and Lipoproteins, Coagulation Factors, and Carbohydrate Metabolism); MARTN010-003367 and MARTN010-003371; MARTN010-003512 and MARTN010-003513-003535 (Effects of Lower Doses of Conjugated Equine Estrogens and Medroxyprogesterone Acetate on Endometrial Bleeding) [Internet]. San Francisco: Drug Industry Document Archive. c2008. Available: http://dida.library.ucsf.edu. Accessed 21 Aug 2009.
20. STRIS014-000675 (HOPE Trial Publication Plan Proposal Year 1 Data). Other supporting documentation: PICKJ038-000119 and PICKJ042-004545; PICKJ038- 000071 and PICKJ038-000065; STRIS014-000674. [Internet]. San Francisco: Drug Industry Document Archive. Available: http://dida.library.ucsf.edu. Accessed 21 Aug 2009.
21. DWRITE065950 [Internet]. San Francisco: Drug Industry Document Archive. Available: http://dida.library.ucsf.edu/tid/jwb37b10. (Note: on this and some of the other documents produced by DesignWrite, the date appearing on the document is inaccurate, reflecting the date the documents were copied by DesignWrite for production to Plaintiffs, not the date the document was actually created. See discussion at Mittleman5022006 at 127-132, May 2, 2006.) Accessed 21 Aug 2009.
22. DWRITE065764 at DWRITE065775 [Internet]. San Francisco: Drug Industry Document Archive. Available: http://dida.library.ucsf. edu/tid/jrb37b10. Accessed 21 Aug 2009.
23. DWRITE066095 at DWRITE066097 [Internet]. San Francisco: Drug Industry Document Archive. Available: http://dida.library.ucsf. edu/tid/kgb37b10. Accessed 21 Aug 2009.
24. GRUBG001-021895-21902 at GRUBG001- 021900 (Premarin/TMG 300-US Publication Plan Proposal. DesignWrite 2003) [Internet]. San Francisco: Drug Industry Document Archive. Available: http://dida.library.ucsf.edu/tid/sac37b10. Accessed 21 Aug 2009.
25. CONTA025-020958 [Internet]. San Francisco: Drug Industry Document Archive. Available: http://dida.library.ucsf.edu/tid/bec37b10. Accessed 21 Aug 2009.
26. Solomon_01262006, January 26, 2006 at 317:14-15 [Internet]. San Francisco: Drug Industry Document Archive. Available: http://dida.library.ucsf.edu/tid/woc37b10. Accessed 21 Aug 2009.
27. Solomon_01272006, January 27, 2006 at 397:22; 398:10 [Internet]. San Francisco: Drug Industry Document Archive. Available: http://dida.library.ucsf.edu/tid/wpb37b10. Accessed 21 Aug 2009.
28. DWRITE076707 (Also see DWRITE066958) [Internet]. San Francisco: Drug Industry Document Archive. Available: http://dida.library.ucsf.edu/tid/rib37b10 and http://dida.library. ucsf.edu/tid/loc37b10. Accessed 21 Aug 2009.
29. Balter W, Skelton M, Safir PO (2003) The P's and Q's of publication planning. Pharm Executive May. pp 130-6.
30. Fugh-Berman A, Melnick D (2008) Off-label promotion, on-target sales. PLoS Med 5: e210.
31. CONTA023-006750 (Publication Planning and Management slideshow) [Internet]. San Francisco: Drug Industry Document Archive. Available: http://dida.library.ucsf.edu/tid/atb37b10. Accessed 21 Aug 2009.
32. CONTA023-007214 (Setting the Scientific Agenda slideshow) [Internet]. San Francisco: Drug Industry Document Archive. Available: http://dida.library.ucsf.edu/tid/atc37b10. Accessed 21 Aug 2009.
33. DESIGN052780-DESIGN052781 [Internet]. San Francisco: Drug Industry Document Archive. Available: http://dida.library.ucsf.edu/tid/duc37b10. Accessed 21 Aug 2009.
34. DESIGN177338 (E-mail correspondence between Karen Mittleman and Sandra Leiblum) [Internet]. San Francisco: Drug Industry Document Archive. Available: http://dida.library. ucsf.edu/tid/exb37b10. Accessed 21 Aug 2009.
35. DESIGN024396 [Internet]. San Francisco: Drug Industry Document Archive. Available: http://dida.library.ucsf.edu/tid/djb37b10. Accessed 21 Aug 2009.
36. DESIGN024724 [Internet]. San Francisco: Drug Industry Document Archive. Available: http://dida.library.ucsf.edu/tid/dkb37b10. Accessed 21 Aug 2009.
37. DESIGN024526 [Internet]. San Francisco: Drug Industry Document Archive. Available: http://dida.library.ucsf.edu/tid/djc37b10. Accessed 21 Aug 2009.
38. DWRITE066498 [Internet]. San Francisco: Drug Industry Document Archive. Available: http://dida.library.ucsf.edu/tid/kub37b10. Accessed 21 Aug 2009.
39. DESIGN175720 at DESIGN175721 and DESIGN175722 [Internet]. San Francisco: Drug Industry Document Archive. Available: http://dida.library.ucsf.edu/tid/ewb37b10. Accessed 21 Aug 2009.
40. STRIS016-031138 [Internet]. San Francisco: Drug Industry Document Archive. Available: http://dida.library.ucsf.edu/tid/wsc37b10. Accessed 21 Aug 2009.
41. DESIGN010191-010204 at DESIGN010193 (Trimegestone -Publication and Abstract Tracking Report) [Internet]. San Francisco: Drug Industry Document Archive. Available: http://dida.library.ucsf.edu/tid/dfc37b10. Accessed 21 Aug 2009.
42. DWRITE065764 at DWRITE065770 (Medical Education and Communication Plan for the Premarin Product Line. Submitted by Design- Write, Inc., Aug 12, 1996) [Internet]. San Francisco: Drug Industry Document Archive. Available: http://dida.library.ucsf.edu/tid/zqc37b10. Accessed 21 Aug 2009.
43. CONTA025-031623 [Internet]. San Francisco: Drug Industry Document Archive. Available: http://dida.library.ucsf.edu/tid/boc37b10. Accessed 21 Aug 2009.
44. DESIGN170355 (E-mail from Gerald Burr, October 11, 1999) [Internet]. San Francisco: Drug Industry Document Archive. Available: http://dida.library.ucsf.edu/tid/elb37b10. Accessed 21 Aug 2009.
45. DESIGN170356-170394, DESIGN170395- 170418, DESIGN170419-170468, DESIGN170469- 170498 and DESIGN170499- 170528 [Internet]. Available: http://dida. library.ucsf.edu. Accessed 21 Aug 2009.
46. DWRITE068884- DWRITE06895 [Internet]. San Francisco: Drug Industry Document Archive. Available: http://dida.library.ucsf.edu/pdf/opc37b10. Accessed 21 Aug 2009.
47. PCSAR001-000927 [Internet]. San Francisco: Drug Industry Document Archive. Available: http://dida.library.ucsf.edu/tid/vpc37b10. Other supporting documentation: DESIGN018080. Available: http://dida.library. ucsf.edu/tid/dhc37b10. DESIGN018239. Available: http://dida.library.ucsf.edu/tid/dic37b10. DWRITE079093 Available: http://d i d a. l ibrar y.uc s f.edu/t id/ruc 3 7 b 1 0; DWRITE068320. Available: http://dida. library.ucsf.edu/tid/oib37b10; CONSG204- 024407. Available: http://dida.library.ucsf. edu/tid/arc37b10 [Internet]. San Francisco: Drug Industry Document Archive. Accessed 15 Feb 2010.
48. DWRITE066543 [Internet]. San Francisco: Drug Industry Document Archive. Available: http://dida.library.ucsf.edu/tid/lcc37b10. Accessed 21 Aug 2009.
49. DWRITE065858 at DWRITE065859 (Strategic Competitive Intelligence on the HRT Market: A source document. Speakers Bureau Meeting) [Internet]. San Francisco: Drug Industry Document Archive. Available: http://dida.library. ucsf.edu/tid/jtb37b10. Accessed 21 Aug 2009.
50. Thorneycroft IH (2001) Prevention of Heart Disease in Women: Is Postmenopausal Estrogen Therapy Warranted? (Point-Counterpoint) The HERS Trial Does Not Confute a Cardioprotective Effect of Hormone Therapy. Menopause Management. July/Aug; 16-28.
51. Mosca L (2000) Hormone Replacement Therapy in the Prevention and Treatment of Atherosclerosis. Current Atherosclerosis Reports 2(4): 297-302.
52. DWRITE066162 [Internet]. San Francisco: Drug Industry Document Archive. Available: http://dida.library.ucsf.edu/tid/kjb37b10. Accessed 21 Aug 2009.
53. Brincat M, Baron Y, Galea R (2005) Estrogens and the skin. Climacteric 8(2): 110-123.
54. Bachman G, Leiblum S (2004) The Impact of Hormones on Menopausal Sexuality: aLiterature Review. Menopause 11(1): 120-130.
55. Eden J (2003 May) Progestins and breast cancer. Am J Obstet Gynecol 188(5): 1123-31. [This article was cited in a staff report for the U.S. Senate Committee on Finance as one of the "examples of articles that Wyeth had paid the medical communications firm, DesignWrite, to outline and draft for target authors." U.S. Sen. Comm. on Finance, Minority Staff Report, Ghostwriting in Medical Literature at 4 & n.6 (June 24, 2010). In a letter to Wyeth cited in the staff report, U.S. Senator Charles Grassley also noted that the article did "not identify the original author." In a judicial opinion published in late 2009, the U.S. Court of Appeals for the Eighth Circuit identified the Eden article as one of the "ghost written articles" commissioned by Wyeth. Scroggin v. Wyeth (In re: Prempro Products Liability Litigation), 586 F.3d 547, 557 (8th Cir. 2009) ("In 2000, Wyeth tapped Dr. John Eden to author 'Breast Cancer and Progestins,' but the true author was a technical writing company, hired to produce the manuscript for Wyeth's approval and Dr. Eden's editing."). Earlier this year, however, the publisher of the American Journal of Obstetrics and Gynecology informed Dr. Eden that, after conducting an investigation, it did not believe the article was ghostwritten.].
56. CONTA025-030538 (Strategic Publications Development Meeting June 15, 2000 Meeting Recap) [Internet]. San Francisco: Drug Industry Document Archive. Available: http://dida. library.ucsf.edu/tid/bob37b10. Accessed 21 Aug 2009.
57. DWRITE003353 (Project Assignment Form) [Internet]. San Francisco: Drug Industry Document Archive. Available: http://dida.library. ucsf.edu/tid/ifc37b10. Accessed 21 Aug 2009.
58. DWRITE065923 at DWRITE065927 [Internet]. San Francisco: Drug Industry Document Archive. Available: http://dida.library.ucsf. edu/tid/juc37b10. Accessed 21 Aug 2009.
59. Curtis M (1999) Selective Estrogen Receptor Modulators: A Controversial Approach for Managing Postmenopausal Health. J Women's Health 8(3): 321-33.
60. DUROJ023-001712 [Internet]. San Francisco: Drug Industry Document Archive. Available: http://dida.library.ucsf.edu/tid/ghb37b10. Accessed 21 Aug 2009.
61. Curtis MG (2001) Comparative Tolerability of First-Generation Selective Estrogen Receptor Modulators in Breast Cancer Treatment and Prevention. Drug Safety 2001;24(14): 1039-53.
62. Ansbacher R (2001) The Pharmacokinetics and Efficacy of Different Estrogens are Not Equivalent. Am J Obstet Gynecol 184(3): 255-63.
63. Warren M (2004) A Comparative Review of the Risks and Benefits of Hormone Replacement Therapy Regimens. Am J Obstet Gynecol 190(4): 1141-67.
64. CONSG204-015605 [Internet]. San Francisco: Drug Industry Document Archive. Available: http://dida.library.ucsf.edu/tid/arb37b10. Accessed 21 Aug 2009.
65. DWRITE065923 at DWRITE065931 [Internet]. San Francisco: Drug Industry Document Archive. Available: http://dida.library.ucsf. edu/tid/juc37b10. Accessed 21 Aug 2009.
66. Janas_010408 at 385:18-24; DWRITE001229 [Internet]. San Francisco: Drug Industry Document Archive. Available: http://dida.library. ucsf.edu/tid/skc37b10. Accessed 21 Aug 2009.
67. Janas_010408 at 388: 19-24, 389: 1-6, 392: 6- 24 and 393: 1-16 [Internet]. San Francisco: Drug Industry Document Archive. Available: http://dida.library.ucsf.edu/tid/skc37b10. Accessed 21 Aug 2009.
68. DWRITE001927 and Janas_010408 at 418: 8- 13 [Internet]. San Francisco: Drug Industry Document Archive. Available: http://dida. library.ucsf.edu/tid/hmc37b10 and http://dida.library.ucsf.edu/tid/skc37b10. Accessed 21 Aug 2009.
69. Janas_010408 at 461: 7-21 [Internet]. San Francisco: Drug Industry Document Archive. Available: http://dida.library.ucsf.edu/tid/skc37b10. Accessed 21 Aug 2009.
70. DWRITE001904 and Janas_010408 at 397: 4- 15 [Internet]. San Francisco: Drug Industry Document Archive. Available: http://dida. library.ucsf.edu/tid/hmb37b10 and http://dida.library.ucsf.edu/tid/skc37b10. Accessed 21 Aug 2009.
71. DWRITE001894 [Internet]. San Francisco: Drug Industry Document Archive. Available: http://dida.library.ucsf.edu/tid/hlc37b10. Accessed 21 Aug 2009.
72. Janas_010408 at 406:14-23 [Internet]. San Francisco: Drug Industry Document Archive. Available: http://dida.library.ucsf.edu/tid/skc37b10. Accessed 21 Aug 2009.
73. DWRITE040906 through DWRITE040938, specifically DWRITE040932 (Exh. 91 to Janas Depos.); Janas_010408 at 471:24-472:3 and 475:3-15 [Internet]. San Francisco: Drug Industry Document Archive. Available: http://dida.library.ucsf.edu/tid/jgb37b10 and http://dida.library.ucsf.edu/tid/skc37b10. Accessed 21 Aug 2009.
74. Janas_010408 at 417 and 429:9-22 (the outline is DWRITE078142, available: http://dida. library.ucsf.edu/tid/rpc37b10); Janas_010408 at 432: 5-9 and DWRITE041313 [Internet]. San Francisco: Drug Industry Document Archive. Available: http://dida.library.ucsf.edu. Accessed 21 Aug 2009.
75. DWRITE001151 [Internet]. San Francisco: Drug Industry Document Archive. Available: http://dida.library.ucsf.edu/tid/hib37b10. Accessed 21 Aug 2009.
76. DWRITE001154 [Internet]. San Francisco: Drug Industry Document Archive. Available from: http://dida.l ibrary.ucsf.edu/tid/hic37b10. Accessed 21 Aug 2009. Also Janas 010408 at 487:19-22. Available: http://dida. library.ucsf.edu/tid/skc37b10. Accessed 7 Feb 2010.
77. DWRITE041522 (the Agreement with the University of Wisconsin) [Internet]. San Francisco: Drug Industry Document Archive. Available: http://dida.library.ucsf.edu/tid/jib37b10. Accessed 21 Aug 2009.
78. DWRITE00113 8, DWRITE001140, DWRITE001143, DWRITE001149, and DWRITE001134 (Letters to authors from B. Janas regarding manuscripts for the April meeting) [Internet]. San Francisco: Drug Industry Document Archive. Available: http://dida.library.ucsf.edu. Accessed 21 Aug 2009.
79. Warren M (2004) A Comparative Review of the Risks and Benefits of Hormone Replacement Therapy Regimens. Am J Ob Gyn 190(4): 1141-67.
80. Supplement (Postmenopausal Hormone Therapy and Breast Health: A Review for Clinicians, October 2001, Supplement to Women's Health in Primary Care) [Internet]. San Francisco: Drug Industry Document Archive. Available: http://dida.library.ucsf.edu/tid/yub37b10. Accessed 21 Aug 2009.
81. DUROJ046-024195 [Internet]. San Francisco: Drug Industry Document Archive. Available: http://dida.library.ucsf.edu/tid/gxc37b10. Accessed 21 Aug 2009.
82. DUROJ046-024196 [Internet]. San Francisco: Drug Industry Document Archive. Available: http://dida.library.ucsf.edu/tid/gyb37b10. Accessed 21 Aug 2009.
83. Janas_010408 at 447:448 [Internet]. San Francisco: Drug Industry Document Archive. Available: http://dida.library.ucsf.edu/tid/skc37b10. Accessed 21 Aug 2009.
84. DWRITE078850 [Internet]. San Francisco: Drug Industry Document Archive. Available: http://dida.library.ucsf.edu/tid/rtb37b10. Accessed 21 Aug 2009.
85. Email communication with George Mejicano, Associate Dean for Continuing Professional Development, September 10, 2009.
86. DWRITE001069 and DWRITE041522 at DWRITE041530 [Internet]. San Francisco: Drug Industry Document Archive. Available: http://dida.library.ucsf.edu/tid/jib37b10 and http://dida.library.ucsf.edu/tid/hdc37b10. Accessed 21 Aug 2009.
87. DWRITE041522 at DWRITE041530, Janas_ 010408 at 420: 21-24 and 421: 1-12 [Internet]. San Francisco: Drug Industry Document Archive. Available: http://dida.library. ucsf.edu/tid/jib37b10 and http://dida.library. ucsf.edu/tid/skc37b10. Accessed 21 Aug 2009.
88. DUROJ017-001102 at DUROJ017-001103 (Publications Planning: Proactive Media Outreach) [Internet]. San Francisco: Drug Industry Document Archive. Available from: http://dida.library.ucsf.edu/tid/fyc37b10. Accessed 7 Feb 2010.
89. DWRITE001850, Janas_010408 415: 17-24 and DWRITE001079 at DWRITE001081 [Internet]. San Francisco: Drug Industry Document Archive. Available: http://dida.library. ucsf.edu. Accessed 21 Aug 2009.
90. DWRITE067764 [Internet]. San Francisco: Drug Industry Document Archive. Available: http://dida.library.ucsf.edu/tid/mtc37b10. Accessed 21 Aug 2009.
91. DWRITE067772 [Internet]. San Francisco: Drug Industry Document Archive. Available: http://dida.library.ucsf.edu/tid/mxb37b10. Accessed 21 Aug 2009.
92. DWRITE067766 [Internet]. San Francisco: Drug Industry Document Archive. Available: http://dida.library.ucsf.edu/tid/mvb37b10. Accessed 21 Aug 2009.
93. DWRITE067767 [Internet]. San Francisco: Drug Industry Document Archive. Available: http://dida.library.ucsf.edu/tid/mvc37b10. Accessed 21 Aug 2009.
94. DWRITE067768 [Internet]. San Francisco: Drug Industry Document Archive. Available: http://dida.library.ucsf.edu/tid/mwb37b10. Accessed 21 Aug 2009.
95. Harris G. Document details plan to promote costly drug [Internet]. New York Times. 2009 Sep 2. Available: http://www.nytimes.com/2009/09/02/business/02drug.html. Accessed 4 Sept 2009.
96. Lexapro FY04 marketing plan [Internet]. 2003 Apr 1. Available: http://www.nytimes.com/packages/pdf/politics/20090831MEDICARE/20090831_M EDICARE.pdf. Accessed 3 Sept 2009.
97. Perrone M. Glaxo used ghostwriting program to promote Paxil [Internet]. Associated Press. 2009 Aug 19. Available: http://www.sfgate.com/cgibin/article.cgi?f=/n/a/2009/08/19/national/w123 616D16.DTL. Accessed 4 Sept 2009.
98. McHenry L (2005) On the Origin of Great Ideas: Science in the Age of Big Pharma. Hastings Ctr Rep 35(6): 17-19.
99. McHenry L, Jureidini J (2008) Industry-Sponsored Ghostwriting in Clinical Trial Reporting: A Case Study. Accountability in Research 15: 152-167.
100. McHenry L (2010) Of Sophists and Spin- Doctors: Industry-Sponsored Ghostwriting and the Crisis of Academic Medicine. Journalology 8(1): 129-145.
101. Mundy A. Dispensing with the Truth. St Martins Press. New York: 2001, 162-167.
102. Landefeld CS, Steinman MA (2009) The Neurontin legacy - marketing through misinformation and manipulation. NEJM 360(2): 103-105.
103. RossJoseph S, Kevin PHill, David SEgilman, Harlan MKrumholz (2008) Guest Authorship and Ghostwriting in Publications Related to Rofecoxib: A Case Study of Industry Documents From Rofecoxib Litigation. JAMA 299(15): 1800-1812.
104. HealyDavid, DinahCattell (2003) Interface between Authorship, Industry and Science in the Domain of Therapeutics. Br J Psych 183: 22-27.
105. Fauber J, Kissinger M. UW linked to ghostwriting [Internet]. Milwaukee Journal Sentinel. 2009 Aug 15. Available: http://www.jsonline.com/features/health/53315032.html. Accessed 18 Aug 2009.
106. Armstrong D. Wall Street Journal. Health Blog: WSJ's blog on health and the business of health [Internet]. Odd ghostwriting offer raises researcher's blood pressure. New York: Dow Jones & Company, Inc, c2009. 2007 Nov 21. Available: http://blogs.wsj.com/health/2007/11/21/odd-ghostwriting-offer-raises- researchersblood- pressure/. Accessed 13 Feb 2009.
107. Singer N. Medical papers by ghostwriters pushed therapy [Internet]. New York Times. 2009 Aug 4. Available: http://www.nytimes.com/2009/08/05/health/research/05ghost.html. Accessed 4 Aug 2009.
108. Wilson D. Drug maker said to pay ghostwriters for journal articles [Internet]. New York Times. 2008 Dec 12. Available: http://www.nytimes. com/2008/12/12/business/13wyeth.html. Accessed 4 Aug 2009.
109. CONTA025-031624 (Outline for Journal Supplement) [Internet]. San Francisco: Drug Industry Document Archive. Available: http://dida. library.ucsf.edu/tid/bpb37b10. Accessed 21 Aug 2009.